Painreform Ltd (PRFX) Stock Price, Quote & News

Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operatio...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 7177050

Website: www.painreform.com

Address:

65 Yigal Alon St., Tel Aviv, Israel

Srknilbrs Sep. 8 at 8:11 PM

$PRFX waiting news coming soon dont miss

0 · Reply

Mack43 Sep. 8 at 2:04 PM

$PRFX I think we can reach $1.50 today. Let's get some volume going.

0 · Reply

DownUpSideway Sep. 8 at 12:43 PM

$PRFX just guru pumping for their own benefit..

1 · Reply

Bridge_Four Sep. 8 at 12:37 PM

$PRFX lol wasn’t this supposed to be worth $48 ?

1 · Reply

alma356m Sep. 8 at 10:21 AM

🧠 Strategy Summary Ticker Setup Type Risk Level Entry Focus $PRFX Low-float squeeze High $1.60 breakout, volume >1M $FORD Speculative pump Very High Only scalp with tight stop $OPEN Trend/swing Moderate $7.00 breakout, support at $6.60 $HOUR VWAP reclaim momentum Moderate $10.50 reclaim, volume

0 · Reply

Jstore12 Sep. 8 at 5:44 AM

Looking to open two new positions to start the week; $UAVS $PRFX Keeping my eyes tuned for any movements with $MNDR and $GNPX this week

0 · Reply

WallStVisions Sep. 7 at 8:34 PM

Everyone’s sleeping on SKYQ… But they’ve got ✔️ A digital asset treasury strategy ✔️ Blockchain utility tied to real-world infrastructure ✔️ Permitted clean-tech site + expanding operations ✔️ Reverse split contingency fully in place ✔️ Still under $0.60 This isn’t just bullish. It’s loaded. $MITQ $QNRX $WLDS $PRFX

1 · Reply

Srknilbrs Sep. 7 at 9:43 AM

$PRFX soon scalping maybe 2+

0 · Reply

PhantomDivine Sep. 6 at 8:01 PM

$PRFX SKYQ has a massive squeeze setup and when more people finds this one, it has the potential to go over $1+. Plus big catalyst ahead, "Company Announces Strategic Digital Asset Initiative." It's trading under book value and the chart is curling. No dilution risk makes this even better. Don't miss out.

0 · Reply

manard85 Sep. 5 at 9:20 PM

$PRFX This could be the dip before the rip. Next week we could be off to the races.

0 · Reply

PainReform/DeepSolar Accepted into NVIDIA Connect Program

Aug 13, 2025, 8:30 AM EDT - 26 days ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

Jul 10, 2025, 8:30 AM EDT - 2 months ago

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

May 27, 2025, 12:12 PM EDT - 3 months ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 7, 2025, 4:30 PM EDT - 4 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

Apr 10, 2025, 8:30 AM EDT - 5 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 7, 2025, 5:00 PM EDT - 5 months ago

PainReform Provides Year-End Business Update

Mar 5, 2025, 11:00 AM EST - 6 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Feb 18, 2025, 8:30 AM EST - 7 months ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Dec 27, 2024, 8:30 AM EST - 9 months ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Nov 20, 2024, 8:30 AM EST - 10 months ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 7, 2024, 5:00 PM EST - 10 months ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Sep 11, 2024, 8:30 AM EDT - 1 year ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 10, 2024, 9:46 AM EDT - 1 year ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

May 31, 2024, 4:15 PM EDT - 1 year ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 15, 2024, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2024

May 8, 2024, 8:30 AM EDT - 1 year ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

Apr 18, 2024, 2:19 PM EDT - 1 year ago

PainReform Announces Closing of $4 Million Public Offering

Apr 9, 2024, 9:00 AM EDT - 1 year ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 2, 2024, 8:30 AM EDT - 1 year ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Jan 22, 2024, 8:30 AM EST - 1 year ago

PainReform to Present at the Microcap Conference in Atlantic City

Jan 3, 2024, 8:30 AM EST - 1 year ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Dec 26, 2023, 6:00 PM EST - 1 year ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Nov 15, 2023, 4:05 PM EST - 1 year ago

PainReform Provides Business Update for the Third Quarter of 2023

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

Jul 19, 2023, 9:00 AM EDT - 2 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 14, 2023, 2:35 PM EDT - 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jun 15, 2023, 8:30 AM EDT - 2 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 7, 2023, 4:30 PM EDT - 2 years ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 15, 2023, 4:45 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2023

May 1, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 2 years ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 16, 2023, 8:00 AM EDT - 2 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Feb 7, 2023, 4:05 PM EST - 2 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Nov 15, 2022, 8:30 AM EST - 3 years ago

PainReform Provides Business Update for the Third Quarter of 2022

Sep 1, 2022, 8:00 AM EDT - 3 years ago

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022, 8:05 AM EDT - 3 years ago

PainReform Provides Business Update for the Second Quarter of 2022

Apr 12, 2022, 9:00 AM EDT - 3 years ago

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

Mar 21, 2022, 9:25 AM EDT - 3 years ago

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

Mar 17, 2022, 8:00 AM EDT - 3 years ago

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

Dec 14, 2021, 8:30 AM EST - 4 years ago

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

Nov 16, 2021, 8:00 AM EST - 4 years ago

PainReform Provides Business Update for the Third Quarter of 2021

Oct 14, 2021, 8:30 AM EDT - 4 years ago

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Srknilbrs Sep. 8 at 8:11 PM

$PRFX waiting news coming soon dont miss

0 · Reply

Mack43 Sep. 8 at 2:04 PM

$PRFX I think we can reach $1.50 today. Let's get some volume going.

0 · Reply

DownUpSideway Sep. 8 at 12:43 PM

$PRFX just guru pumping for their own benefit..

1 · Reply

Bridge_Four Sep. 8 at 12:37 PM

$PRFX lol wasn’t this supposed to be worth $48 ?

1 · Reply

alma356m Sep. 8 at 10:21 AM

0 · Reply

Jstore12 Sep. 8 at 5:44 AM

Looking to open two new positions to start the week; $UAVS $PRFX Keeping my eyes tuned for any movements with $MNDR and $GNPX this week

0 · Reply

WallStVisions Sep. 7 at 8:34 PM

1 · Reply

Srknilbrs Sep. 7 at 9:43 AM

$PRFX soon scalping maybe 2+

0 · Reply

PhantomDivine Sep. 6 at 8:01 PM

0 · Reply

manard85 Sep. 5 at 9:20 PM

$PRFX This could be the dip before the rip. Next week we could be off to the races.

0 · Reply

prasan2015 Sep. 5 at 8:42 PM

$PRFX could this be next hour

0 · Reply

StockLionLew Sep. 5 at 8:05 PM

$PRFX glad I got out of this on yesterday smh

0 · Reply

ShadowSnake Sep. 5 at 7:51 PM

$PRFX up 12% yesterday only to give it all back… damn

0 · Reply

manard85 Sep. 5 at 7:06 PM

$PRFX

0 · Reply

Zokbar Sep. 5 at 6:22 PM

$PRFX This one looks great here for a few day swing

0 · Reply

cannabischickin2772 Sep. 5 at 6:19 PM

$PRFX gunna hold thru till Monday at least

0 · Reply

Mjm1980411 Sep. 5 at 4:29 PM

$PRFX how’s the chart look?

0 · Reply

Mjm1980411 Sep. 5 at 3:33 PM

$PRFX Lets go green please!!!

0 · Reply

Rangort22 Sep. 5 at 3:10 PM

$PRFX @MS_Tammy is holding over the weekend....must be a reason. She always says do whats best for you. Im holding. Leta see how this plays out !

2 · Reply

noname10000 Sep. 5 at 2:42 PM

$PRFX added nicely and easy

0 · Reply

Mjm1980411 Sep. 5 at 2:37 PM

$PRFX wonder when more will jump in for a scalp.

0 · Reply

ShadowSnake Sep. 5 at 2:31 PM

$PRFX up 12% yesterday just to give it all back … dammit

0 · Reply

Market Cap	2.86M
Revenue (ttm)	0.00
Net Income (ttm)	-14.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	252,884
Avg Vol	3,645,562
Day's Range	N/A - N/A
Shares Out	2.01M
Stochastic %K	14%
Beta	0.58
Analysts	Strong Buy
Price Target	$47.99